Cellectis SA-ADR

Cellectis S.A. is a French clinical-stage biopharmaceutical company headquartered in Paris, with offices in New York City and Raleigh, North Carolina. Operating internationally, the firm develops treatments that harness the immune system via the use of proprietary gene editing technologies. The company's focus is on the development of therapies for use in treatments for cancer immunotherapy. Cellectis was established in 1999. The firm is in the process of developing a unique allogeneic approach for CAR-T immunotherapies in oncology. It also provides life-saving UCART product candidates that aim to address unmet needs in patients suffering from various types of cancer, including acute myeloid leukaemia (AML), multiple myeloma (MM), Hodgkin lymphoma (HL), and non-Hodgkin lymphoma (NHL). The company’s technologies are primarily used in oncology research and pharmaceutical drug discovery programs, as well as in the areas of agronomics, bioproduction, and biotherapeutics. Cellectis has built on its expertise in combining meganucleases with engineered targeting DNA matrices into meganuclease recombination systems (MRS). These solutions are used for gene excision, correction, and replacement. The firm is publicly listed on the NASDAQ, where it trades under the ticker CLLS. To keep track of Cellectis price movements, add CLLS stock to your eToro watchlist and start receiving real-time updates.